




The relative strengths and weaknesses of Matinas Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas Biopharma Holdings Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 15% points. The greatest weakness of Matinas Biopharma Holdings Inc is the variable Net Income, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 89%, being 165% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	2,805
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,118
Liabilities, Non-Current	0
Other Assets	216
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	15
Other Net Income	244
Other Revenues	0
Property and Equipment	340
Research and Development	5,176
Selling, General and Administrative Expense	5,289

Output Variable	Value in 1000 USD
Assets	3,361
Liabilities	1,134
Expenses	10,465
Revenues	0
Stockholders Equity	2,228
Net Income	-10,221
Comprehensive Net Income	-10,221
BaseVar	7,602
ECR before LimitedLiability	-239%
Economic Capital Ratio	89%